Thoracic surgeon David Jones and medical oncologist Charles Rudin, internationally recognized leaders in their fields, to head the Thoracic Surgical Service and the Thoracic Oncology Service, respectively.
In our recently updated guides to non-small cell and small-cell lung cancers, you can learn about diagnosis, treatment, follow-up care, lung cancer experts, and clinical trials at Memorial Sloan-Kettering.
Memorial Sloan-Kettering was one of the first centers to use this type of genetic testing for lung cancer patients and is currently one of the only centers testing for mutations in squamous cell carcinomas of the lung.
In an extraordinary demonstration of excellence, five Memorial Sloan-Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.
A study led by thoracic surgeon Prasad Adusumilli found that an abnormal cell pattern identified in the tumor tissue of some lung cancer patients may help to predict which tumors are more likely to recur after surgery.
A new study detected one of ten such mutations in 54 percent of the 516 lung cancer patients tested at diagnosis. The results enabled doctors to select the most appropriate drug designed to block the identified mutation and choose other treatment options for those patients whose tumors did not have a mutation.
A new study by researchers at Memorial Sloan-Kettering Cancer Center reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone - the two most prominent sites of lung cancer relapse.